By effectively modulating the androgen receptor (AR) and JAK2/STAT3 signaling pathways, it emerges as a compelling targeted therapeutic strategy, making it a promising candidate for treating metastatic prostate cancer (15). This evidence concerns the gene AR and metastatic prostate carcinoma.